Senhwa Biosciences, Inc. engages in the development of novel drugs and special active pharmaceutical ingredients. The company offers novel drugs, a small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) for the treatment of breast cancer and other homologous repair deficiency (HRD) or solid tumors from BRCA1/2 gene mutation; inhibitor of protein kinase CK2 (casein kinase II); and Silmitasertib (CX4945) for the treatment of cholangiocarcinoma, basal cell carcinoma, and medulloblastoma. It also provides technical advice and consulting services. Senhwa Biosciences, Inc. is based in New Taipei City, Taiwan.
Frequently asked questions
What sector does Senhwa Biosciences, Inc. (6492) operate in?
Senhwa Biosciences, Inc. belongs to the Other sector and operates in the Biotechnology industry.
What is Senhwa Biosciences, Inc. (6492) current stock price?
As of the latest data, Senhwa Biosciences, Inc. stock price is NT$38.05, with a previous close of NT$38.70. Senhwa Biosciences, Inc. lost -NT$0.65 in the last trading session, representing a -1.68% loss.
What is Senhwa Biosciences, Inc. (6492) current market capitalization?
Senhwa Biosciences, Inc. market cap is approximately 3.46 billion.
What is Senhwa Biosciences, Inc. (6492) Earnings Per Share (EPS)?
The trailing EPS is -NT$2.98.
Does Senhwa Biosciences, Inc. (6492) pay dividends?
No. Senhwa Biosciences, Inc. does not pay a dividend.
What is Senhwa Biosciences, Inc. (6492) beta (volatility) score?
Senhwa Biosciences, Inc. has a beta of 0.771, indicating lower volatility than the overall market.
